18F-FDG PET/CT for detection of metastatic infection in gram-positive bacteremia

Journal of Nuclear Medicine

Volumn 51, Issue 8, 2010, Pages 1234-1240

  Vos, Fidel J ^a   Bleeker Rovers, Chantal P ^a   Sturm, Patrick D ^a   Krabbe, Paul F M ^a   Van Dijk, Arie P J ^a   Cuijpers, Maria L H ^a   Adang, Eddy M M ^a   Wanten, Geert J A ^a   Kullberg, Bart Jan ^a   Oyen, Wim J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

18F FDG PET CT; Bacteremia; Metastatic infection; Staphylococcus aureus

Indexed keywords

ANTIBIOTIC AGENT; FLUORODEOXYGLUCOSE F 18; ANTIINFECTIVE AGENT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ABDOMINAL INFECTION; ADULT; ARTICLE; BACTEREMIA; BACTERIAL ARTHRITIS; BACTERIAL ENDOCARDITIS; BACTERIAL GROWTH; BLOOD CULTURE; CARDIOVASCULAR INFECTION; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENTEROCOCCUS; EYE INFECTION; FOLLOW UP; GRAM POSITIVE INFECTION; HEPATITIS; HIGH RISK PATIENT; HUMAN; INFECTION RISK; KIDNEY INFECTION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORTALITY; OSTEOMYELITIS; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTHESIS INFECTION; PSOAS ABSCESS; PYEMIA; RELAPSE; SENSITIVITY AND SPECIFICITY; SOFT TISSUE INFECTION; SPLEEN INFECTON; SPONDYLITIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; SURVIVAL; TREATMENT DURATION; AGED; BIOASSAY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CROSS INFECTION; FEMALE; KAPLAN MEIER METHOD; MICROBIOLOGY; MIDDLE AGED; RISK FACTOR; SCINTISCANNING; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; CROSS INFECTION; ENDPOINT DETERMINATION; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; STREPTOCOCCAL INFECTIONS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 77956222054     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.072371     Document Type: Article

References (19)

1. Jensen AG, Wachmann CH, Espersen F, Scheibel J, Skinhoj P, Frimodt- Moller N. Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases. Arch Intern Med. 2002;162:25-32.
2. Verhagen DW, van der Meer JT, Hamming T, de Jong MD, Speelman P. Management of patients with Staphylococcus aureus bacteraemia in a university hospital: a retrospective study. Scand J Infect Dis. 2003;35:459-463.
3. Lautenschlager S, Herzog C, Zimmerli W. Course and outcome of bacteremia due to Staphylococcus aureus: evaluation of different clinical case definitions. Clin Infect Dis. 1993;16:567-573. (Pubitemid 23121074)
4. Julander I. Unfavourable prognostic factors in Staphylococcus aureus septicemia and endocarditis. Scand J Infect Dis. 1985;17:179-187.
5. Cuijpers ML, Vos FJ, Bleeker-Rovers CP, et al. Complicating infectious foci in patients with Staphylococcus aureus or Streptococcus species bacteraemia. Eur J Clin Microbiol Infect Dis. 2007;26:105-113.
6. Jensen AG, Espersen F, Skinhoj P, Frimodt-Moller N. Bacteremic Staphylococcus aureus spondylitis. Arch Intern Med. 1998;158:509-517.
7. Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30:633-638.
8. Bleeker-Rovers CP, Vos FJ, de Kleijn EM, et al. A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol. Medicine (Baltimore). 2007;86:26-38.
9. de Kleijn EM, Vandenbroucke JP, van der Meer JW. Fever of unknown origin (FUO). I. A prospective multicenter study of 167 patients with FUO, using fixed epidemiologic entry criteria. The Netherlands FUO Study Group. Medicine (Baltimore). 1997;76:392-400.
10. Vos FJ, Bleeker-Rovers CP, Corstens FH, Kullberg BJ, Oyen WJ. FDG-PET for imaging of non-osseous infection and inflammation. Q J Nucl Med Mol Imaging. 2006;50:121-130.
11. 18F-FDG PET in detecting metastatic infectious disease. J Nucl Med. 2005;46:2014-2019.
12. Fowler VG Jr, Olsen MK, Corey GR, et al. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med. 2003;163: 2066-2072.
13. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet. 2005; 366:1435-1442.
14. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications - a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association - endorsed by the Infectious Diseases Society of America. Circulation. 2005;111:e394-e434.
15. Fowler VG Jr, Sanders LL, Sexton DJ, et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis. 1998;27:478-486.
16. de Groot M, Meeuwis AP, Kok PJ, Corstens FH, Oyen WJ. Influence of blood glucose level, age and fasting period on non-pathological FDG uptake in heart and gut. Eur J Nucl Med Mol Imaging. 2005;32:98-101.
17. Hill EE, Vanderschueren S, Verhaegen J, et al. Risk factors for infective endocarditis and outcome of patients with Staphylococcus aureus bacteremia. Mayo Clin Proc. 2007;82:1165-1169.
18. Lesens O, Hansmann Y, Storck D, Christmann D. Risk factors for metastatic infection in patients with Staphylococcus aureus bacteremia with and without endocarditis. Eur J Intern Med. 2003;14:227-231.
19. Gopal AK, Fowler VG Jr, Shah M, et al. Prospective analysis of Staphylococcus aureus bacteremia in nonneutropenic adults with malignancy. J Clin Oncol. 2000;18:1110-1115.